Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price

Key Points

• Royal Bank of Canada raised its price target on Pacira to $24 and maintained a "sector perform" rating, implying roughly a 1.8% downside from the stock's current level.
• Pacira showed underlying commercial momentum—EXPAREL volume and revenue grew ~5–7% year‑over‑year—but its FY‑2026 revenue guidance of $745M–$770M landed slightly below consensus, which pressured the stock.
• Analysts are mixed (three Buy, three Hold, one Sell) with an average rating of "Hold" and an average target of $29.40; institutional ownership is very high (~99.7%) and insiders have sold shares recently (32,261 shares over the past 90 days).

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) had its price target upped by equities researchers at Royal Bank Of Canada from $22.00 to $24.00 in a research note issued on Friday,Benzinga reports. The firm currently has a "sector perform" rating on the stock. Royal Bank Of Canada's target price would suggest a potential downside of 1.84% from the stock's current price.

A number of other brokerages have also recently issued reports on PCRX. Zacks Research upgraded Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Tuesday, April 7th. Barclays reduced their price objective on Pacira BioSciences from $27.00 to $25.00 and set an "equal weight" rating for the company in a report on Thursday, March 26th. Needham & Company LLC lifted their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Friday. HC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of Pacira BioSciences in a research report on Friday, January 9th. Finally, Wall Street Zen downgraded shares of Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $29.40.

Pacira BioSciences Stock Performance

Shares of NASDAQ:PCRX traded down $1.04 during trading on Friday, reaching $24.45. 949,474 shares of the stock were exchanged, compared to its average volume of 809,524. Pacira BioSciences has a 12 month low of $18.80 and a 12 month high of $27.64. The firm has a market cap of $961.62 million, a PE ratio of 160.40 and a beta of 0.19. The stock has a 50-day moving average price of $23.31 and a 200-day moving average price of $23.14. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The firm had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. During the same quarter in the prior year, the firm earned $0.91 EPS. The company's revenue was up 5.1% on a year-over-year basis. Research analysts expect that Pacira BioSciences will post 1.85 EPS for the current fiscal year.

Insider Activity

In other news, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the completion of the sale, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shawn Cross sold 12,941 shares of Pacira BioSciences stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total transaction of $325,595.56. Following the completion of the sale, the chief financial officer owned 105,341 shares of the company's stock, valued at approximately $2,650,379.56. The trade was a 10.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 32,261 shares of company stock worth $785,850. Corporate insiders own 6.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Doma Perpetual Capital Management LLC increased its holdings in shares of Pacira BioSciences by 49.7% during the third quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company's stock worth $69,613,000 after buying an additional 897,255 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Pacira BioSciences by 0.5% during the third quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company's stock worth $55,751,000 after buying an additional 11,831 shares in the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company's stock worth $50,925,000 after buying an additional 565,288 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Pacira BioSciences by 16.6% during the third quarter. American Century Companies Inc. now owns 1,378,513 shares of the company's stock worth $35,524,000 after buying an additional 196,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock worth $27,454,000 after buying an additional 367,869 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Q1 results beat expectations — Pacira reported $0.60 EPS vs. $0.55 expected and revenue of $177.4M vs. $171.8M expected; revenue grew ~5% YoY and EXPAREL volume rose ~7%, showing underlying commercial momentum. View Press Release
• Positive Sentiment: Pipeline and clinical progress — management completed enrollment in a Phase 3 ZILRETTA shoulder OA study (topline readout expected by year-end) and is advancing PCRX‑201 Phase II work, supporting longer‑term upside from new assets. Press Release — Q1 & pipeline
• Positive Sentiment: Analyst upgrade — Needham raised its price target to $32 and reiterated a Buy, implying ~28% upside from the current ~ $25 area; this can attract buyers and provide a positive sentiment tailwind. Benzinga
• Neutral Sentiment: Earnings materials and call — the earnings presentation and full call transcript are available for details on commercial trends, margin commentary and channel dynamics; useful for investors who want to dig into product-level performance. Earnings Presentation Call Transcript
• Negative Sentiment: FY-2026 revenue guidance came in at $745M–$770M, slightly under the consensus (~$761.5M); the guidance range (and any conservatism in EPS detail) is likely the main reason the stock is under pressure despite the beat — investors may wait for clearer cadence before pushing shares significantly higher. Guidance & pipeline update
• Neutral Sentiment: Be aware of ticker overlap — recent press releases referencing “PCRX” on Canadian exchanges relate to PharmaCorp RX Inc. TSXV: PCRX, not Pacira; avoid confusing the two when scanning headlines or news feeds. PharmaCorp release (unrelated)

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.